Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience.
BACKGROUND
Human immunodeficiency virus (HIV)-infected patients are at increased risk for squamous cell carcinoma of the anal canal (SCCA) and the incidence of SCCA has increased in the era of highly active antiretroviral therapy. The outcome of SCCA in HIV-positive patients has not been evaluated in prospective trials and the published literature is limited to retrospective case series. The aim of this study is to describe the treatment, toxicity, and overall survival (OS) in patients with and without HIV infection.


METHODS
We performed a retrospective chart review of all patients treated for invasive SCCA at Karmanos Cancer Institute, Wayne State University from 1991 to 2007 and collected data regarding HIV status, demographics, stage at diagnosis, treatment, response to treatment, toxicity, and survival.


RESULTS
Forty-five patients with SCCA were identified, of whom 13 were HIV-positive and 32 were HIV-negative. HIV-positive patients were younger (median age, 45 vs. 57 years) and had a higher frequency of men (89% vs. 37%). Patients were balanced for presenting stage at diagnosis and rates of local recurrence were found to be similar between the 2 groups. HIV-positive patients were less likely to receive full dose chemoradiotherapy. Except for dermatitis, the incidence of grade 3 to 4 toxicities was similar in both groups. Median OS was 33.5 months for HIV-positive patients and 71.8 months for HIV-negative patients. Although limited by the small size of the study, the OS was not statistically significantly different by HIV status (P = 0.787).


CONCLUSIONS
Although the HIV-positive patients received lower dose chemoradiotherapy, no major difference in local control or overall survival was observed.
Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Nazik
N
Hammad
Lance K
LK
Heilbrun
Sachin
S
Gupta
Nishant
N
Tageja
Philip A
PA
Philip
Anthony F
AF
Shields
Daryn
D
Smith
Bassel F
BF
El-Rayes
D000328:Adult; D001741:Black or African American / Q000706:statistics & numerical data; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active; D001005:Anus Neoplasms / Q000453:epidemiology / Q000628:therapy / Q000821:virology*; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000628:therapy / Q000821:virology*; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008824:Michigan / Q000453:epidemiology; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D015995:Prevalence; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin